Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

Table 2 Best overall responses

	Number	Percent
PB regimen (n = 51)
CR	0	0.0
PR	26	51.0
SD	20	39.2
PD	5	9.8
NE	0	0.0
ORR (CR + PR)	26	51.0
95% CI	36.6–65.3
DCR (CR + PR + SD)	46	90.2
95% CI	78.6–96.7
Maintenance treatment with eribulin (n = 45)
CR	0	0.0
PR	29	64.4
SD	13	28.9
PD	3	6.7
ORR (CR + PR)	29	64.4
95% CI	48.8–78.1
DCR (CR + PR + SD)	42	93.3
95% CI	81.7–98.6

BP bevacizumab + paclitaxel, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, DCR disease control rate, CI confidence interval

ISSN: 1471-2407